HBV PUBLIC HEALTH IMPLICATIONS

Similar documents
Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)

Diagnostic Methods of HBV and HDV infections

NATURAL HISTORY OF HEPATITIS B

HEPATITIS B: are escape mutants of concern?

Viral Hepatitis Diagnosis and Management

Mutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey

Trends in molecular diagnostics

The Alphabet Soup of Viral Hepatitis Testing

Laboratory for Clinical and Biological Studies, University of Miami Miller School of Medicine, Miami, FL, USA.

29th Viral Hepatitis Prevention Board Meeting

Bible Class: Hepatitis B Virus Infection

HBsAg(+) mothers is a transient

Basics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology

SEROLOGICAL STATUS OF HEPATITIS B VIRUS INFECTION AMONG MONKS AND NOVICES AT BUDDHIST MONASTERIES IN THREE TOWNSHIPS, YANGON

Occult Hepatitis B Infection: why, who and what to do?

Isolated Hepatitis B Core Antibody

Management of Chronic Hepatitis B in Asian Americans

Chronic Hepatitis B Infection

CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

Laboratory and Clinical Diagnosis of HCV Infection

Learning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.

Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B

The Hepatitis B-e antigen-positive

Test Name Results Units Bio. Ref. Interval

Evidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand

Hepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature

Chronic Hepatitis B: management update.

Acute Hepatitis B Virus Infection with Recovery

Elimination of Perinatal Hepatitis B Transmission

Uses and Misuses of Viral Hepatitis Testing. Origins of Liver Science

Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a

HBV : Structure. HBx protein Transcription activator

Chapter 5 Serology Testing

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

Viral hepatitis. The word hepatitis means inflammation of the liver. There are five main types of viral hepatitis: A, B, C, D, E

HBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of

IN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST

Lab Underwriting Puzzler. Presented by: Bill Rooney, M.D.

HBV in HIV Forgotten but not Gone

Test Name Results Units Bio. Ref. Interval

The ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses

INTERPRETING HEPATITIS B SEROLOGY

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)

NH2 N N N O N O O P O O O O O

Test Name Results Units Bio. Ref. Interval

ESCMID Online Lecture Library. by author

S401- Updates in the Treatments of Hepatitis B & C

Molecular Diagnosis Future Directions

Bristol-Myers Squibb

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016

ARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update

Rama Nada. - Malik

The ABC s (and D & E s) of the Viral Hepatitides Part 2 DIAGNOSTIC TESTS 3/7/2013

Cryptogenic cirrhosis is a diagnosis made after excluding

STATE TDAP VACCINE PROGRAM

Title: Reactivation of a Hepatitis B without core antibody: a case report.

Impact of multi-dye multiplex technology on testing algorithm

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013

HBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

NAT Screening of Blood Donations in NBC, TRCS

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

Hepatitis B vaccine: long-term efficacy, booster policy, and impact of HBV mutants on hepatitis B vaccination programmes

Hepatitis Serology and Background Notes

PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA

Final Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

CDC website:

MA PERINATAL HEPATITIS B PREVENTION PROGRAM

Management of Hepatitis B - Information for primary care providers

The Evolving Landscape of Preventing Maternal-Fetal Hepatitis B Infections

(DNA) Real-time PCR. Exicycler 96 Rotor-Gene Q/6000 PCR

W ith an estimated million people worldwide

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

La riattivazione dell epatite virale nel paziente in terapia biologica

Cornerstones of Hepatitis B: Past, Present and Future

4th International HIV/Viral Hepatitis Co-Infection Meeting

Don t interfere My first choice is always nucs!

Hepatitis delta: often forgotten?

Hepatitis C. Core slides

Anti-HBc: state of the art what is the CORE of the issues?

DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE

HBV Core and Core-Related Antigen Quantitation in Chinese Patients with. Chronic Hepatitis B Genotype B and C Virus Infection

Professor Vincent Soriano

WHO recommendations. Diagnostic testing in infants

Experience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control

Hepatitis A-E Viruses. Dr Nemes Zsuzsanna

[DOI] /j.issn , China

The effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors

Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011

Natural History of HBV Infection

EAST LONDON INTEGRATED CARE

Viral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH

HIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg

The natural course of chronic HBV infection can be divided into four, which are not always continuous.

Virological Tools and Monitoring in the DAA Era

Hepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019

Considerations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection

Transcription:

جزايری دکتر سيد محمد آزمايشگاه ھپاتيت B -دانشکده بھداشت ويروس شناسی- گروه دانشگاه علوم پزشکی تھران کنگره ارتقا کيفيت- ١٣٩٢

HBV PUBLIC HEALTH IMPLICATIONS 2 billion people have been infected by HBV worldwide. 350 400 million suffer from chronic HBV infection of whom 25% will die of chronic liver disease or HCC. HCC and liver failure are the main cause of death and currently over 500,000 people die each year from the consequences of HBV infection (52,000 from acute and 470,000 from cirrhosis or liver cancer). The World Health Organization places hepatitis B virus (HBV) in the top 10 causes of death worldwide.

HBV Genomic Structure

Proposed Model of Major Hydrophilic Region (MHR). Jazayeri et al, 2012

Serology Serology tests are easy to use, inexpensive, and are the best tests for initial screening. Despite the increase sensitivity of serologic tests, a residual risk of viral hepatitis transmission still exists. HBsAg becomes detectable in acute infection when HBV DNA reaches a concentration above approximately 2000 copies per ml.

HBsAg False Negativity HBsAg may not be detected under the following circumstances: 1. Window period (in the post acute phase when HBs antigen declines or immune complexes are present) 2. Low level carrier 3. Resolving infection (under the detection limit of the assay in chronic infection who eliminate HBsAg for many years). 4. S gene mutants 5. HBV with HDV/HCV/HIV / co infection.

Quantitative Assays Several techniques for viral hepatitis quantification are employed such as: Signal l amplification Target amplification i

Target amplification Techniques 1. PCR (standard/conventional) 2. Real Time PCR Quantitative PCR 1. COBAS Amplicor (ROCHE) 2. Superquant (National Genetics Ins) 3. Target Capture (ABI) Transcription mediated amplification (TMA) Nucleic Acid Sequence Based Amplification (NASBA) NucliSens (BioMerieux)

Real Time PCR Advantages A high h degree of automation ti with minimized i i hands on time and minimized risk of cross contamination. ti No post PCR steps Rapid detection Broad dynamic range (10 10 10 copies) Multiplex approach possible High precision High technical sensitivity The sensitivity of real time PCR is 5 10 copy/ml. Reproducibility (CV < 2.0 %)

Measurement of viral load Indicator of disease activity Quantification of antiviral efficacy Early detection of resistant virus Dynamics on therapy may be predictor of outcome Occult O l HBV & HCV

Correlation between HBV DNA levels, serology and histology during chronic HBV infection HBsAg + HBeAg + HBeAg -/Anti-HBe + HBV DNA <10 10 10-10 12 >10 5 5 >10 5 ALT, Histology IMMUNOTOLERANT IMMUNOACTIVE IN-ACTIVE CARRIER REACTIVATION PHASE PHASE (HBsAg-/ANTI-HBs + )

Comparison between different HBV viral load quantitation assays Assay Method Sensitivity Digene hybrid-capture II ultra sensitive (Digene corp) Versant HBV DNA 3.0 (bdna) (Bayer Diagnostics) Cobas amplicor HBV monitor (Roche molecular systems) Cobas TaqMan 48 HBV (Roche molecular systems) Real art HBV PCR assay (Artus- Biotech) Hybrid capture signal amplification Semi-automated bdna signal amplification Semi-automated quantitative RT-PCR Real time PCR Real time PCR 4700 copies/ml 2000 copies/ml 200 copies/ml <50 copies/ml <50 copies/ml

Quantitation assays Problems Generating divergent results. Need for standardization of assays for the detection of viral hepatitis.

HBV Seroconstellation Case report (1)

Aim of Study To explore the unusual serologic clinical features in chronic HBV patients by applying highly sensitive molecular tests.

Methodology 55 HBsAg negative g chronic carriers with various serologic pictures were enrolled in the study. All patients were negative for antibodies against hepatitis i C, hepatitis i D and human immunodeficiency virus. None had prior anti HBV therapy.

Methodology HBV DNA was extracted using Qiagen Mini Blood Kit. HBV DNA was determined in all samples by real time PCR. The positive samples were selected for standard PCR reactions. Direct sequencing of surface genes was carried Direct sequencing of surface genes was carried out by an automated sequencer.

5 Results (1) 4 3 2 1 Ladder Pos Neg

Results (2) Samples (Cases) Surface Antigen Mutation(s) 1 Q129R, P153T 2 Y134H, S136F 3 Outside of a determinant (S193L,Y205F,S207T,L209V,S210R,P211H) 4 R122FT125I R122F,T125I,A128L 5 Y134H, S136F

HBV Seroconstellation Case report (2) prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG

OBI Definition Occult Hepatitis B infection is defined as: Detectable HBV DNA Among Patients Negative For HBsAg. Occult HBV infection had not been well studied sudeduntil HBV Vpoy polymerase sechain reaction (PCR) became available.

A schematic phylogenetic tree showing the association of occult hepatitis B in different clinical settings. The length of each branch symbolizes the weight of published papers for those settings. Jazayeri et al, 2012.

Aim of Study The aim of this study was to : 1. To find out the prevalence of OBI in children born to HBsAg carriers. 2. To analyze variations in the HBV genomic sequence that might ih play a role in breakthrough h HBV infection despite Immunoprophylaxis.

Methodology 75 children born to HBsAg positive mothers who subsequently were immunized against HBV using a dose of HBIG and three standard injections of vaccine at zero, one and six months intervals were traced.

Children Immunized by HBV Vaccine & HBIG HBsAg Negative HBsAg Test

Children Immunized by HBV Vaccine & HBIG HBsAg Negative HBsAg Test Real Time PCR

Children Immunized by HBV Vaccine & HBIG HBsAg Negative HBsAg Test Real Time PCR

Children Immunized by HBV Vaccine & HBIG HBsAg Negative HBsAg Test Real Time PCR OBI

Children Immunized by HBV Vaccine & HBIG HBsAg Negative HBsAg Test Real Time PCR OBI Standard PCR

Children Immunized by HBV Vaccine & HBIG HBsAg Negative HBsAg Test Real Time PCR OBI Gunther Methodology Standard PCR

Children Immunized by HBV Vaccine & HBIG HBsAg Negative HBsAg Test Real Time PCR OBI Gunther Methodology Standard PCR Sequencing

Children Immunized by HBV Vaccine & HBIG HBsAg Negative HBsAg Test Real Time PCR OBI Gunther Methodology Standard PCR Sequencing

Children Immunized by HBV Vaccine & HBIG HBsAg Negative HBsAg Test Real Time PCR OBI Gunther Methodology Standard PCR Sequencing Mutational Analysis

Real Time PCR Results no.real-time PCR 28% Pos Neg 72% Real Time PCR (TaqMan) was positive i in 21 (28%), all were below 10 4 copy/ml.

Demographic, serologic and virologic data of occult HB positive patients. Sample Code Age α Sex* Anti HBc Anti HBs Titer(mIU/mL) HBV DNA (copy/ml) 14 16 2 + >100 2100 40 15 1 30 2000 42 61 1 28 55 46 128 1 18 77 52 17 2 >100 1270 56 18 1 >100 81 65 32 1 95 3800 67 38 2 38 415 72 37 1 >100 223 84 57 1 36 9240 86 63 2 >100 474 103 12 1 >100 468 106 66 2 >100 1920 108 35 2 >100 347 110 10 1 + >100 500 112 22 1 47 450 115 10 1 + 38 1200 116 64 2 25 4560 616 23 1 47 2330 122 12 2 + >100 2300 125 72 2 + 94 395

Results of Conventional PCR All Real Time Positive samples were confirmed by standard PCRs at least for one site of HBV genome. The most specific region used in our method was the pre-s gene. Overall, four (19%) samples were positive for all five regions (full genome), seven (33%) for three regions, one (5%) for two regions and eight (38%) for one region

Direct Sequencing Results of HBV surface Protein obtained from Occult-Infected Children a determinant Mutations Causing Undetectability of sera by Serology

Amino acid changes in different proteins of HBV in OBI positive cases.

Results of Mutational Analysis Altogether, 13 patients had at least one amino acid mutation within different HBV genome interfere in either functional and/or immune epitope activity. Eight OBI positive cases did not have any Eight OBI positive cases did not have any mutations at all.

Conclusion Serodiscordant d cases Mutation within the a determinant displayed altered binding to antibodies and cannot be detected by diagnostic assays. As point amino acid mutations have been observed in our cases, we believe that these are escape mutants. The use of sensitive molecular tests such as real time PCR would be helpful lfl in solving li these problems.